Mink Therapeutics reported a remarkable clinical response wherein a testicular cancer patient achieved complete remission following administration of their off-the-shelf invariant natural killer T-cell therapy Agent-797 combined with nivolumab. Published in Nature’s Oncogene, the case displayed durable remission with no detectable disease two years post single infusion, triggering a 730% surge in the company’s stock. This development underscores the therapeutic potential of allogeneic NK T-cell therapies in cancer treatment.